Potential therapeutic and pharmacological strategies for SARS-CoV2

被引：0
|
作者：
Doaa A. Ghareeb
Samar R. Saleh
Mohammed S. Nofal
Mohamed M. Y. Kaddah
Salma. F. Hassan
Inas K. Seif
Sally A. El-Zahaby
Shaimaa M. Khedr
Marwa Y. Kenawy
Aliaa A. Masoud
Salma A. Soudi
Ahmed A. Sobhy
Jaillan G. Sery
Miral G. Abd El-Wahab
Alshimaa A. Abd Elmoneam
Abdulaziz Mohsen Al-mahallawi
Maha A. El-Demellawy
机构：
[1] Alexandria University,Biological Screening and Preclinical Trial Laboratory, Department of Biochemistry, Faculty of Science
[2] City of Scientific Research and Technological Applications (SRTA-City),Pharmaceutical and Fermentation Industries Development Centre (PFIDC)
[3] Pharos University in Alexandria,Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy
[4] City of Scientific Research and Technological Applications (SRTA-City),Fabrication Technology Department, Advanced Technology and New Materials Research Institute (ATNMRI)
[5] Alexandria University,Clinical Pharmacy Program, Faculty of Pharmacy
[6] Cairo University,Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy
[7] October University for Modern Sciences and Arts (MSA),Department of Pharmaceutics, Faculty of Pharmacy
[8] GEBRI,Medical Biotechnology Department
[9] SRTA-City,undefined
来源：
Journal of Pharmaceutical Investigation | 2021年 / 51卷
关键词：
COVID-19; Hydroxychloroquine; Indomethacin; Tocilizumab; Teicoplanin; Camostat;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：281 / 296
页数：15
相关论文
共 50 条
  • [41] Neurological Involvements of SARS-CoV2 Infection
    Amin Gasmi
    Torsak Tippairote
    Pavan Kumar Mujawdiya
    Asma Gasmi Benahmed
    Alain Menzel
    Maryam Dadar
    Geir Bjørklund
    Molecular Neurobiology, 2021, 58 : 944 - 949
  • [42] The pathogenesis and alternative treatment of SARS-CoV2
    Choi, Jun-Yong
    Joo, Myungsoo
    INTEGRATIVE MEDICINE RESEARCH, 2020, 9 (03)
  • [43] Paediatric SARS-COV2 infections in Switzerland
    Uka, A.
    Zimmermann, P.
    Ritz, N.
    SWISS MEDICAL WEEKLY, 2021, 151 : 13S - 13S
  • [44] SARS-CoV2 vaccines: Slow is fast
    Green, Douglas R.
    SCIENCE ADVANCES, 2020, 6 (28)
  • [45] Therapeutic approaches on the interaction between SARS-CoV2 and ACE2: a biochemical perspective
    Baskol, Gulden
    Mazicioglu, Mumtaz M.
    Ozel, Merve
    TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, 2020, 45 (06): : 643 - 650
  • [46] Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies
    Hussain, Arif
    Hasan, Anwarul
    Babadaei, Mohammad Mahdi Nejadi
    Bloukh, Samir Haj
    Chowdhury, Muhammad E. H.
    Sharifi, Majid
    Haghighat, Setareh
    Falahati, Mojtaba
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 130
  • [47] Milk Peptides as Novel Multi-Targeted Therapeutic Candidates for SARS-CoV2
    Pradeep, H.
    Najma, Umme
    Aparna, H. S.
    PROTEIN JOURNAL, 2021, 40 (03): : 310 - 327
  • [48] Susceptibility of SARS-CoV2 infection in children
    Cotugno, Nicola
    Amodio, Donato
    Buonsenso, Danilo
    Palma, Paolo
    EUROPEAN JOURNAL OF PEDIATRICS, 2023, 182 (11) : 4851 - 4857
  • [49] Artemisia annua inhibits SARS-Cov2
    不详
    DEUTSCHE ZEITSCHRIFT FUR AKUPUNKTUR, 2021, 64 (03): : 233 - 233
  • [50] Developing lectins as inhibitors of SARS-CoV2
    Guseman, Alex J.
    Murphy, Linda
    Nambulli, Sham
    Bhinderwhala, Fatema
    Duprex, Paul
    Gronenborn, Angela M.
    BIOPHYSICAL JOURNAL, 2022, 121 (03) : 332A - 332A
12345